Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김현진 | - |
dc.date.accessioned | 2022-03-23T00:37:34Z | - |
dc.date.available | 2022-03-23T00:37:34Z | - |
dc.date.issued | 2020-07 | - |
dc.identifier.citation | ADVANCES IN THERAPY, v. 37, no. 9, page. 3839-3849 | en_US |
dc.identifier.issn | 0741-238X | - |
dc.identifier.issn | 1865-8652 | - |
dc.identifier.uri | https://link.springer.com/article/10.1007/s12325-020-01443-6 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/169324 | - |
dc.description.abstract | Introduction Use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) only, beta-blockers (BB) only, or both has been rarely compared in patients with heart failure (HF). We evaluated the prescribing patterns of ACEi/ARB and BB on prognosis in HF according to left ventricular function. Methods Study data were obtained from a national multicenter cohort that included patients hospitalized for HF. Patients were classified into four groups according to the prescription pattern at discharge: all ACEi/ARB and BB treatment group, only ACEi or ARB treatment group, only BB treatment group, and neither ACEi/ARB nor BB group. Results Use of both ACEi/ARB and BB had significantly lowest all-cause death rates among the four groups in all types of HF. Cox regression analysis showed that use of both drugs was independently associated with 51% reduced risk of all-cause death in patients with HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF). Treatment with only ACEi/ARB also showed an independent association with a 52% reduction in this group. However, only BB treatment was not associated with reducing long-term mortality in patients with HFpEF and HFmrEF. In patients with HF with reduced ejection fraction, use of ACEi/ARB and/or BB revealed an independent association with a reduced risk of all-cause death regardless of prescribing patterns. Conclusions Prescribing patterns were diverse in HF and there was a difference in the degree of risk reduction in all-cause death. In particular, clinicians should consider ACEi/ARB first for patients with HFpEF and HFmrEF prior to BB. | en_US |
dc.language.iso | en | en_US |
dc.publisher | SPRINGER | en_US |
dc.subject | Angiotensin-converting enzyme inhibitor | en_US |
dc.subject | Angiotensin receptor blockers | en_US |
dc.subject | Beta-blocker | en_US |
dc.subject | Ejection fraction | en_US |
dc.subject | Heart failure | en_US |
dc.title | Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure | en_US |
dc.type | Article | en_US |
dc.relation.no | 9 | - |
dc.relation.volume | 37 | - |
dc.identifier.doi | 10.1007/s12325-020-01443-6 | - |
dc.relation.page | 3839-3849 | - |
dc.relation.journal | ADVANCES IN THERAPY | - |
dc.contributor.googleauthor | Kim, Hyun-Jin | - |
dc.contributor.googleauthor | Jo, Sang-Ho | - |
dc.contributor.googleauthor | Lee, Min-Ho | - |
dc.contributor.googleauthor | Seo, Won-Woo | - |
dc.contributor.googleauthor | Choi, Jin-Oh | - |
dc.contributor.googleauthor | Ryu, Kyu-Hyung | - |
dc.relation.code | 2020050405 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | titi8th | - |
dc.identifier.researcherID | AAJ-2905-2021 | - |
dc.identifier.orcid | https://orcid.org/0000-0002-7885-1695 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.